|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Regeneron Pharmaceuticals Inc., Rensselaer
| | | Phone: | (518) 488-6000 | Fax: | (518) 488-6030 | Year Established: | 1988 | Ticker: | REGN | Exchange: | NASDAQ | Main Contact: | Marion McCourt, Senior VP, Head of Commercial | | Other Contacts: | Jay Markowitz, M.D., Senior VP, Portfolio Management Kristine Erickson, O.D., Ph.D., VP, Clinical Research Joseph J. LaRosa, Senior VP, General Counsel & Secretary Daniel Van Plew, Senior VP, GM, Industrial Operations & Product Supply Peter Powchik, MD, Senior VP, Clinical Development Neil Stahl, Ph.D., Senior VP, Research and Development Sciences Robert E. Landry, Senior VP, Finance & CFO George D. Yancopoulos, MD, Ph.D., Executive VP, CSO & President, Regeneron Research Leonard S. Schleifer, MD, PhD, President & CEO
| | Company Description | Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain and has preclinical programs in other diseases and disorders.
Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.
The Company's ability to develop product candidates is enhanced by the application of several proprietary technologies that Regeneron has incorporated into a comprehensive drug discovery and development process. This process is designed to thoroughly understand the biology of specific diseases, discover potential therapeutic candidates, and evaluate these candidates in clinical trials. One specific area of Regeneron expertise is the rapid development of fully-human monoclonal antibodies. In November 2007, Regeneron and sanofi-aventis entered into a global, strategic collaboration to discover, develop, and commercialize fully-human therapeutic antibodies utilizing Regeneron's proprietary VelociSuite of technologies.
In addition to the Company's corporate headquarters and research laboratories in Tarrytown, New York, Regeneron has a large-scale biologics manufacturing facility in Rensselaer, New York, where it produces commercial and investigational products for its clinical trials. | |
|
|
|